Thursday, July 23, 2009

Understanding Types Of Malignant Mesothelioma

Understanding the Epithelial, Surcomatoid and the Biphasic types of the malignant mesothelioma

2009-07-22 - (mesotheliomacancernews.com - Mesothelioma Press Release) - Dallas, TX - Facts about mesothelioma cancer are fairly known to many and specially to those who are affected with mesothelioma cancer. Yet, with this rare disease harming those who have been closely associated with asbestos, exposing themselves to asbestos fibers at their work place or through the family members who brought the dust of silver fiber at home in the work cloths, shoes, hair while returing from work.

The fact noted here is that no one who comes into contact with asbestos is spared from its lethal effects whether its is a direct asbestos industry workers or the worker of the industry that produces goods in which asbestos is used as a raw material and the family members, their friends and loved ones of these workers. Thus, the number of people who get effected from asbestos fibers easily and surely multiplies.

Epithelial mesothelioma, Sarcomatoid mesothelioma, malignant biphasic mesothelioma

1) The Epithelial mesothelioma: Approximately 50% to 70% of mesothelioma cells are the epithelial cells. These cells are tubular in pattern and are of uniform shape. These cells develop in the mesothelioma that protects certain organs of the gastrointestinal tract and the lungs.

Treatment of these epithelial cells is based on the three traditional therapies of surgery, radiation and chemotherapy. Sometimes, two therapies are combined for the treatment, depending upon the intensity of the infection.

2) The sarcomatoid mesothelioma: These cells are irregular and oval in shape. The nucleus is difficult to detect. These cells further divide into secondary cells and are classified as the 'acinar 'cells, the' clear'' cells and the 'tubo-papillary' cells. About 10% to 15% of the total mesothelioma cancer patients belong to this class of cells. This type of the cells lead towards death.

The treatment is the same as of the mesothelioma epithelial cells. But, these sarcomatoid cells are very resistant to these treatments. Help of other therapies such as the immunotherapy, the gene therapy and the photodynamic therapy proves helpful.

3) The malignant biphasic mesothelioma: 40% to 60% of the mesothelioma cancer patients belong to this class, The biphasic system is a combination of both the epithelial and the sarcomatoid types of mesothelioma.

Treatment is the same as prescribes for the above two types, with a few variations, depending upon the stage and level of the disease.

Thus, with the knowledge and the development in treatment and therapies, the sad part is, that all mesothelioma cancer cases are fatal.

Monday, June 01, 2009

Drug Toxicity Assay Kits Increase Drug Development Efficiency

Bioo Scientific's Toxicity Assay Kits Increase the Efficiency of Drug Development

Bioo Scientific announced the launch of the MaxDiscoveryT Toxicity Assay Kits for the monitoring of toxic effects in in vivo preclinical studies.

Austin, TX, May 31, 2009 -- Since toxicity is one of the leading causes of drug failures, measuring preclinical toxicity is a critical drug development function. Accurate in vivo toxicity assays are essential to lowering attrition and increasing efficiency in drug development.

Bioo Scientific announced today the launch of their MaxDiscoveryT Toxicity Assay Kits. These kits monitor in vivo toxicity by measuring liver and heart function in serum samples. They provide simple, convenient, colorimetric determination of well-characterized functional markers of for liver and heart. They are ideal tools to monitor toxic effects caused by administration of siRNA, DNA plasmids, transfection agents or other therapeutic treatments during preclinical studies. The assays can be used in a range of mammals, including mice and rats, providing a powerful tool to assess and reduce the toxicity of drugs formulations and to improve drug delivery methods.

According to Dr Joe Krebs, Director of Protein Chemistry and Engineering at Bioo Scientific, "MaxDiscoveryT Toxicity kits are designed to provide researchers with rapid, cost-effective tools required to address the escalating challenges of drug development in today's competitive landscape."

Assays are available for alanine transaminase, aspartate transminase, alkaline phosphatase, lactate dehydrogenase, cholesterol, and creatine kinase.

About Bioo Scientific
Bioo Scientific Corporation is a global biotechnology tools company, headquartered in Austin, Texas. Bioo Scientific provides innovative products and services to academic researchers, pharmaceutical and biotechnology companies, molecular diagnostics laboratories, and customers who perform food and feed safety analysis.

Contact Information
Bioo Scientific
Dawn Obermoeller
512-301-4094
dawn@redbridgemarketing.com
www.biooscientific.com

Monday, April 06, 2009

Truck Drivers At Greater Risk For Lung Cancer

Diesel Users Suffer More Lung Cancer; a Simple Solution is to Hand from ChemEcol and VEPower

Those who work with and at close proximity to diesel engines, especially lorry drivers, are at a higher risk of cancer according to a recent US study. This is on top of the elevated risk of "heart disease and stroke, possibly resulting from enhanced coagulation and arterial thrombosis" such exposure gives. The good news is that a British company has developed a fuel technology that is seen to significantly reduce ultra fine particulate emissions by as much as 45%.

Welwyn Garden City, United Kingdom, March 28, 2009 -- Truckers endure such grave risks as lung cancers, heart disease and stroke all the time they run their engines. But it's not just the lorry drivers who are at risk. The American study also saw that those working with the and near trucks (fork truck drivers, warehousemen, mechanics, and even office workers) are at elevated risk from these killers. Why?

Diesel exhaust carries particulate matter; this is what colours it smoky black. Particulates are both created by and carriers of toxic substances called polycyclic aromatic hydrocarbons (PAHs). Many of these are known to be particularly carcinogenic, mutagenic. Some of these particles are small enough (100nm or less) to be classified as nanoparticles. These have been found to become distributed around the body via the blood supply once inhaled with notable deposits being found in the liver and heart. If ingested (when particles have settled on food or in drink) they will also pass into the gastro-intestinal tract (4).

It's not just haulage workers and their colleagues who are at risk. Black carbon (again, part of the exhaust) exposure in city children has been shown to reduce development in terms of intelligence (5). The particulate matter we have been looking at is known also to exacerbate respiratory complaints, allergies such as asthma and may agitate some skin complaints also. Some studies have found that certain particulate constituents can be carcinogenic on the skin as well as when inhaled (6).

ChemEcol (UK) Ltd. makes the combustion enhancer Additone. The technology has been developed as a response to the grave threats posed by vehicle exhaust pollution. ChemEcol's products are not based on metallic catalysts, nano-technology or otherwise, as such would counteract the goal of reducing particulate pollutant emissions (the metallic particles would be exhausted along with the other emissions). In fact this technology is based on pure hydrocarbon formulations, maintaining the physical properties of the diesel.

ChemEcol's patented technology modifies the processes of fuel combustion inside the engine, reducing the particulates produced at the most fundamental level. This has a beneficial side-effect of reducing fuel consumption as the PAHs otherwise produced can be considered to be wasted fuel. This change then reduces CO2 emissions and costs by an average of 3%.

VEPower Ltd markets ChemEcol's product. They can be reached at ChemEcol on +44 (0) 1707 330400, at www.chemecol.net and neil@chemecol.net.

Contact Information
ChemEcol Ltd
Nel Faulkner
+44 (0) 20 3286 8771
neil@chemecol.net
www.chemecol.net


 

Tuesday, February 17, 2009

Record Year For Asbestos Claims

Field Fisher Waterhouse reports record year for Asbestos Claims Group

WEBWIRE - Monday, February 16, 2009 - In 2008, the Asbestos Claims Group at law firm Field Fisher Waterhouse LLP recovered record levels of compensation for victims of asbestos-related diseases in 124 successful cases, resulting in over £16 million. Over the years, the lawyers in the firm's Asbestos Claims Group have recovered a total of £132 million in 2025 successful claims.

Some of the significant asbestos claims cases over the past year have included:

- Negotiating an award of £703,000 for the widow and family of a 52 year old partner in an engineering firm who died from mesothelioma following exposure to asbestos at work. This is amongst only a handful of awards exceeding £500,000 across England and Wales.*

- Winning £100,000 damages (plus legal costs) for a retired teacher who developed mesothelioma by using drawing pins to pin children's work to the walls of her prefab classroom, which contained asbestos.**

- In a landmark case the firm recovered £12,500 for the value of hospice care as part of a £170,000 settlement for a man who worked with asbestos in 1963 and contracted mesothelioma in 2005. The funding of hospice care is almost exclusively by charitable donation and this is thought to be the first time a firm of solicitors has recovered the cost of care in this way.***

- Field Fisher Waterhouse acted for the family of a 75 year old man who died due to mesothelioma, and who used to take care of his grandchildren after school in term times. The defendants initially denied that this was compensatable, since there was no reported precedent for it, however the firm recovered £109,352 at a High Court hearing including £27,960 for the grandchildren's care.****

The FFW team of asbestos lawyers has also been actively lobbying the House of Commons, requesting that the Government overturn the House of Lords ruling that pleural plaques - a scarring of the lining of the lungs as a result of exposure to asbestos - is not a compensatable disease. The team also responded to the Ministry of Justice's consultation on the Law Lords' pleural plaques ruling.

Asbestos-related diseases affect thousands of people in the UK each year. Factory workers and labourers are amongst those who are commonly affected, but Field Fisher Waterhouse has also acted on behalf of professionals such as doctors, nurses and teachers who have been exposed to asbestos through their work. Field Fisher Waterhouse LLP is a leader in the field of Asbestos Claims.

Rodney Nelson-Jones, head of the Asbestos Claims group at Field Fisher Waterhouse, said: "I am delighted that in 2008 we were able to win over £16 million in compensation for the victims of these terrible diseases. It is crucial that sufferers and their families receive the compensation they deserve"

About Field Fisher Waterhouse
Field Fisher Waterhouse LLP is a full-service European law firm with offices in Brussels, Hamburg and London. With 119 partners, over 200 other lawyers and nearly 300 support staff, FFW assist a wide range of international clients, advising across a full range of legal issues. The main areas of practice are corporate and commercial, IP and technology, banking and finance, regulatory and real estate. Field Fisher Waterhouse LLP also have particular expertise in competition & EU law, dispute resolution, employment, asbestos claims and mesothelioma claims, personal injury, spinal injury cases and medical negligence, public sector and tax.

Contact Information
    Louise Eckersley
    PR Manager
    Field Fisher Waterhouse LLP
    020 7861 4120
    enquiries@pr-sending.co.uk

For further press information please contact:
Louise Eckersley
PR Manager
Field Fisher Waterhouse LLP
35 Vine Street
London EC3N 2AA United Kingdom
020 7861 4120
www.personalinjury.ffw.com

Related Links
    Asbestos Claims
    Personal Injury
    Medical Negligence

Thursday, December 11, 2008

Years of Potential Life Lost From Asbestos Exposure

Asbestosis-Related Years of Potential Life Lost Before Age 65 Years --- United States, 1968--2005

Exposure to asbestos fibers can cause asbestosis and other diseases (1) after a latency of 10--40 years from initial exposure to onset of illness. Asbestos still is used in the United States (approximately 2,200 metric tons in 2006) in certain products manufactured domestically (2). In addition, an undocumented amount of asbestos continues to be imported in products manufactured elsewhere, and a substantial amount of asbestos remains in existing buildings and manufactured products. An estimated 1.3 million construction and general industry workers in the United States potentially are exposed to asbestos each year, mainly from manipulation of asbestos during renovation or demolition activities (3). Also, although asbestos ore is no longer mined in the United States (4), some U.S. mine workers might remain at risk for exposure to asbestos contained in other ores. To characterize trends in premature mortality attributed to asbestosis in the United States, CDC analyzed annual underlying cause-of-death data for 1968--2005, the most recent years for which data were available.* This report describes the results of that analysis, which indicated that annual years of potential life lost before age 65 years (YPLL) attributed to asbestosis increased 64%, from an average of 146.0 YPLL per year during 1968--1972 to 239.6 per year during 2001--2005 (regression trend for the 5-year moving average, p<0.001), for an overall total of 7,267 YPLL (mean per decedent: 6.2) over the entire period. These results demonstrate that asbestosis-attributable YPLL continue to occur and that efforts to prevent, track, and eliminate asbestosis need to be maintained.

For this analysis, decedents for whom the International Classification of Diseases (ICD) code for asbestosis was listed as the underlying cause of death were identified from 1968--2005 mortality data.? Given the occupational etiology and long latency of asbestosis, analysis was restricted to deaths of persons aged >25 years. Standard industry and occupation information that met CDC quality criteria was available for decedents in 26 states during the 1985--1999 period.§ After 1999, funds for coding industry and occupation were not available, and coding at the state level ceased. The number of states reporting data in any particular year varied from 16 to 22, and the number of years of data available for any one state varied from 2 to 15. Industry and occupation were classified according to two U.S. Census Bureau coding systems.¶ YPLL and mean YPLL were calculated using 5-year age groups and standard methodology (5). A simple linear regression model was used for time-trend analysis of YPLL (using 5-year moving averages).

During 1968--2005, asbestosis was identified as the underlying cause of death for 9,024 decedents. Of these, 1,169 (13.0%) were aged 25--64 years, including one (0.1%) decedent aged 25--34 years; 17 (1.5%) aged 35--44 years; 165 (14.1%) aged 45--54 years; and 986 (84.3%) aged 55--64 years, accounting for 7,267 YPLL (mean per decedent: 6.2). The majority of asbestosis decedents aged 25--64 years were male (1,125 [96.2%]) and white (1,064 [91.0%]), accounting for 7,038 (96.8%) and 6,470 (89.0%) YPLL, respectively (Table 1).

YPLL attributed to asbestosis deaths increased 64%, from an average of 146.0 per year during 1968--1972 to 239.6 per year during 2001--2005 (regression trend, p<0.001). YPLL varied annually, from a low of 69 (mean per decedent: 8.6) in 1973 to a high of 306 (mean per decedent: 5.9) in 1990 (Figure). The rate varied annually, from a low of 0.73 per million in 1973 to a high of 2.78 per million in 1970. During 1968--2005, asbestosis deaths in Texas (85; 577 YPLL), Pennsylvania (99; 544 YPLL), New Jersey (90; 527 YPLL), and California (76; 468 YPLL) accounted for 29.9% of all decedents aged 25--64 years with asbestosis as the underlying cause of death and 29.1% of the total YPLL attributed to asbestosis (Table 1).

Industry and occupation information was available for 153 (28.8%) of the 531 decedents aged 25--64 years with asbestosis as the underlying cause of death during 1985--1999 (Table 2). Of 54 industries reported, the greatest YPLL were in construction (244 YPLL; mean per decedent: 5.7); ship and boat building and repairing (41; mean per decedent: 5.9); and military (41; mean per decedent: 5.9). Of 59 occupations reported, the greatest YPLL were for insulation workers (112; mean per decedent: 5.9); managers and administrators, not elsewhere classified (43; mean per decedent: 7.2); and plumbers, pipefitters, and steamfitters (42; mean per decedent: 4.7).

Reported by: JM Mazurek, MD, JM Wood, MS, Div of Respiratory Disease Studies, National Institute for Occupational Safety and Health, CDC.

Editorial Note:
YPLL are a measure of premature mortality that emphasizes deaths occurring among younger persons during their most productive years (5,6). Persons dying before age 65 years are considered as having years of potential work tenure lost, on the assumption that these are a worker's most productive years. During 1968--2005, asbestosis was identified as the underlying cause of death for 1,169 decedents aged 25--64 years, accounting for 7,267 YPLL. Overall, a mean of 6.2 YPLL per decedent was attributed to asbestosis during 1968--2005, indicating that, on average, decedents aged 25--64 years with asbestosis listed as the underlying cause of death died at age 58 years. Despite the decline in asbestos use and reduced exposures, the findings described in this report indicate that asbestosis-attributable YPLL continue to occur. Because asbestosis mortality typically manifests several decades after initial exposure to asbestos, much of the continuing YPLL likely is attributed to exposures experienced decades ago. During 1970--2004, the annual number of asbestosis-related deaths (based on the analysis of asbestosis deaths coded on the entity axis in multiple cause-of-death files**) in the United States increased nearly 17-fold, from 89 (age-adjusted death rate: 0.6 per million persons aged >15 years) in 1970 to 1,493 (6.9) in 2000, and then declined slightly to 1,470 (6.3) in 2004, for an overall total of 25,413 asbestosis deaths over the entire period (7). This slight decline in the age-adjusted death rate was attributed to several factors, including reduced use of asbestos and improved control of asbestos exposure (8,9). Beginning several decades ago, increased awareness of the health consequences of asbestos exposure stimulated voluntary and regulatory actions by the Environmental Protection Agency and the Occupational Safety and Health Administration (8,9).

Available data (for 153 decedents) indicated that the greatest industry-specific YPLL values were associated with work in construction and ship and boat building and repairing, which is consistent with documented past industry-specific asbestos exposures (1). Likewise, two of the three occupations with the greatest YPLL values, insulation workers and plumbers, pipefitters, and steamfitters, are well known to have been associated with asbestos exposures.

The findings in this report are subject to at least six limitations. First, this report used a death certificate--based definition of asbestosis as the underlying cause of death. Because some deaths from asbestosis might have been attributed to other diseases (e.g., idiopathic pulmonary fibrosis) instead of to asbestosis, the findings in this report likely underestimate deaths and YPLL attributable to asbestosis. Second, complete work histories are not listed on death certificates, and the relevance of the reported usual industry and occupation to actual hazardous exposures could not be verified. Although no studies have examined the accuracy of usual industry and occupation information on death certificates specifically for asbestosis decedents, research suggests a generally good agreement of this information compared with that from other sources (10). Third, coded information on usual industry and occupation were available for decedents in only 26 states, accounting for 28.8% of all U.S. asbestosis decedents during 1985--1999. Thus, these data might not be nationally representative for 1985--1999. Fourth, the state issuing a death certificate is not always the state in which the decedent's asbestos exposure occurred. Fifth, ICD cause-of-death codes used in this analysis changed twice during 1968--2005. However, these revisions likely did not introduce bias or affect the temporal trend in asbestosis deaths (7). Finally, YPLL, as calculated, do not account for the full burden of asbestosis. During the period for which CDC analyzed U.S. death data, approximately 87% of the deaths with asbestosis listed as the underlying cause of death occurred in persons aged >65 years. Moreover, although YPLL do reflect premature mortality during the most productive years of life, YPLL do not account for all reduced quality of life or work years lost attributed to disability from asbestosis. Persons with asbestosis can live for many years with severely limited lung function and few treatment options, leading to inability to work.

The continuing occurrence of cases of asbestos in younger persons (asbestosis-attributable YPLL) underscores the need for persistent asbestosis prevention and elimination efforts. Effective primary prevention is critical because asbestos-related diseases can develop or progress even after occupational exposure ends. Guidance for persons concerned about exposure to asbestos and for health-care providers who work with patients potentially exposed to asbestos is available at
http://www.cdc.gov/health/asbestos.htm. CDC continues to conduct surveillance for asbestosis and other asbestos-related deaths to follow trends and identify problems.

Acknowledgments

This report is based, in part, on contributions by RM Castellan, MD, and PJ Middendorf, PhD, National Institute for Occupational Safety and Health, CDC.
References

   1. Rom WN. Asbestos-related lung disease. In: Fishman AP, Elias JA, Fishman JA, Grippi MA, Senior RM, Pack AI, eds. Fishman's pulmonary diseases and disorders. 4th ed. New York, NY: McGraw-Hill Medical; 2008:943--58.

   2. Kelly TD, Matos GR. Historical statistics for mineral and material commodities in the United States: US Geological Survey data series 140. Reston, VA: US Geological Survey; 2007. Available at
http://minerals.usgs.gov/ds/2005/140.

   3. US Department of Labor. Better protection against asbestos in the workplace. Fact sheet no. OSHA 92-06. Available at
http://www.pp.okstate.edu/ehs/training/oshasbes.htm.

   4. Van Gosen BS. Reported historic asbestos mines, historic asbestos prospects, and natural asbestos occurrences in the eastern United States. US Geological Survey open-file report 2005--1189. Reston, VA: US Geological Survey; 2006. Available at
http://pubs.usgs.gov/of/2005/1189.

   5. Wise RP, Livengood JR, Berkelman RL, Goodman RA. Methodological alternatives for measuring premature mortality. Am J Prev Med 1988;4:268--73.

   6. CDC. Premature mortality in the United States: public health issues in the use of years of potential life lost. MMWR 1986;35(2 Suppl):1S--11S.

   7. Bang KM, Mazurek JM, Syamlal G, Wood JM. Asbestosis mortality surveillance in the United States, 1970--2004. Int J Occup Environ Health 2008;14:161--9.

   8. US Environmental Protection Agency. EPA asbestos materials bans: clarification. Available at
http://www.epa.gov/oppt/asbestos/pubs/asbbans2.pdf.

   9. Martonik JF, Nash E, Grossman E. The history of OSHA's asbestos rule makings and some distinctive approaches that they introduced for regulating occupational exposure to toxic substances. AIHAJ 2001;62:208--17.

  10. Steenland K, Beaumont J. The accuracy of occupation and industry data on death certificates. J Occup Med 1984;26:288--96.

* Since 1968, CDC's National Center for Health Statistics (NCHS) has compiled multiple cause-of-death data annually from death certificates in the United States. CDC's National Institute for Occupational Safety and Health (NIOSH) extracts information on deaths from occupationally related respiratory diseases and conditions from the NCHS data and stores the information in the National Occupational Respiratory Mortality System (NORMS), available at
http://webappa.cdc.gov/ords/norms.html.

? ICDA-8 code 515.2 (asbestosis) for years 1968--1978, ICD-9 code 501 (asbestosis) for years 1979--1998, and ICD-10 code J61 (pneumoconiosis due to asbestos and other mineral fibers) for years 1999--2005. For years 1999--2005, decedents with ICD-10 underlying cause coded as J65 (pneumoconiosis associated with tuberculosis) or J92.0 (pleural plaque with presence of asbestos) also were included in the underlying cause-of-death tabulation for asbestosis if code J61 also was listed on the death certificate.

§ Alaska, Colorado, Georgia, Hawaii, Idaho, Indiana, Kansas, Kentucky, Maine, Missouri, Nebraska, Nevada, New Hampshire, New Jersey, New Mexico, North Carolina, Ohio, Oklahoma, Rhode Island, South Carolina, Tennessee, Utah, Vermont, Washington, West Virginia, and Wisconsin.

¶ Industry and occupation information from death certificates was coded on the NCHS multiple cause-of-death data files according to the 1980 U.S. Bureau of Census Index of Industries and Occupations classification system from1985 to 1992, and according to the 1990 U.S. Bureau of Census classification system from 1993 to 1999. For the industries and occupations listed in this report, the 1980 and 1990 classification system codes and titles were the same.

** Entity axis includes information on all of the diseases, injuries, or medical complications, as well as the location (part, line, and sequence) of the information recorded on each death certificate. "Detail Record Layout" available at
http://www.cdc.gov/nchs/about/major/dvs/mcd/1998mcd.htm.

Original article is located here:
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5749a1.htm